130 related articles for article (PubMed ID: 8386282)
1. Inhibition of Epstein-Barr virus-mediated capping of CD21/CR2 by alpha interferon (IFN-alpha): immediate antiviral activity of IFN-alpha during the early phase of infection.
Delcayre AX; Lotz M; Lernhardt W
J Virol; 1993 May; 67(5):2918-21. PubMed ID: 8386282
[TBL] [Abstract][Full Text] [Related]
2. The Epstein-Barr virus-binding site on CD21 is involved in CD23 binding and interleukin-4-induced IgE and IgG4 production by human B cells.
Henchoz-Lecoanet S; Jeannin P; Aubry JP; Graber P; Bradshaw CG; Pochon S; Bonnefoy JY
Immunology; 1996 May; 88(1):35-9. PubMed ID: 8707347
[TBL] [Abstract][Full Text] [Related]
3. Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.
Delcayre AX; Salas F; Mathur S; Kovats K; Lotz M; Lernhardt W
EMBO J; 1991 Apr; 10(4):919-26. PubMed ID: 1849076
[TBL] [Abstract][Full Text] [Related]
4. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23.
Frémeaux-Bacchi V; Bernard I; Maillet F; Mani JC; Fontaine M; Bonnefoy JY; Kazatchkine MD; Fischer E
Eur J Immunol; 1996 Jul; 26(7):1497-503. PubMed ID: 8766552
[TBL] [Abstract][Full Text] [Related]
5. Analysis of host gene expression changes reveals distinct roles for the cytoplasmic domain of the Epstein-Barr virus receptor/CD21 in B-cell maturation, activation, and initiation of virus infection.
Arredouani MS; Bhasin MK; Sage DR; Dunn LK; Gill MB; Agnani D; Libermann TA; Fingeroth JD
J Virol; 2014 May; 88(10):5559-77. PubMed ID: 24600013
[TBL] [Abstract][Full Text] [Related]
6. Soluble recombinant CR2 (CD21) inhibits Epstein-Barr virus infection.
Nemerow GR; Mullen JJ; Dickson PW; Cooper NR
J Virol; 1990 Mar; 64(3):1348-52. PubMed ID: 2154612
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Epstein-Barr virus infection in vitro and in vivo by soluble CR2 (CD21) containing two short consensus repeats.
Moore MD; Cannon MJ; Sewall A; Finlayson M; Okimoto M; Nemerow GR
J Virol; 1991 Jul; 65(7):3559-65. PubMed ID: 1645784
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr viruses that express a CD21 antibody provide evidence that gp350's functions extend beyond B-cell surface binding.
Busse C; Feederle R; Schnölzer M; Behrends U; Mautner J; Delecluse HJ
J Virol; 2010 Jan; 84(2):1139-47. PubMed ID: 19889766
[TBL] [Abstract][Full Text] [Related]
9. Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells.
Martin DR; Marlowe RL; Ahearn JM
J Virol; 1994 Aug; 68(8):4716-26. PubMed ID: 7913508
[TBL] [Abstract][Full Text] [Related]
10. Binding sites of the Epstein-Barr virus and C3d receptor (CR2, CD21) for its three intracellular ligands, the p53 anti-oncoprotein, the p68 calcium binding protein and the nuclear p120 ribonucleoprotein.
Barel M; Balbo M; Gauffre A; Frade R
Mol Immunol; 1995 Apr; 32(6):389-97. PubMed ID: 7753047
[TBL] [Abstract][Full Text] [Related]
11. Characterization of an Epstein-Barr virus receptor on human epithelial cells.
Birkenbach M; Tong X; Bradbury LE; Tedder TF; Kieff E
J Exp Med; 1992 Nov; 176(5):1405-14. PubMed ID: 1383386
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
[TBL] [Abstract][Full Text] [Related]
13. Human complement receptor type 1/CD35 is an Epstein-Barr Virus receptor.
Ogembo JG; Kannan L; Ghiran I; Nicholson-Weller A; Finberg RW; Tsokos GC; Fingeroth JD
Cell Rep; 2013 Feb; 3(2):371-85. PubMed ID: 23416052
[TBL] [Abstract][Full Text] [Related]
14. Pep34, a synthetic peptide whose sequence corresponds to the intracytoplasmic domain of the Epstein-Barr virus receptor (CR2, CD21), regulates human B lymphocyte proliferation triggered through CR2.
Balbo M; Barel M; Bouillie S; Drane P; Cassinat B; Frade R
Mol Immunol; 1995 Nov; 32(16):1295-8. PubMed ID: 8559153
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus infection of human gastric carcinoma cells: implication of the existence of a new virus receptor different from CD21.
Yoshiyama H; Imai S; Shimizu N; Takada K
J Virol; 1997 Jul; 71(7):5688-91. PubMed ID: 9188650
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human complement receptor type 2 (CR2/CD21) as a receptor for IFN-alpha: a potential role in systemic lupus erythematosus.
Asokan R; Hua J; Young KA; Gould HJ; Hannan JP; Kraus DM; Szakonyi G; Grundy GJ; Chen XS; Crow MK; Holers VM
J Immunol; 2006 Jul; 177(1):383-94. PubMed ID: 16785534
[TBL] [Abstract][Full Text] [Related]
17. Expression of EBV/C3d receptors on T cells: biological significance.
Tsoukas CD; Lambris JD
Immunol Today; 1993 Feb; 14(2):56-9. PubMed ID: 8383497
[TBL] [Abstract][Full Text] [Related]
18. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human cell surface triggers pp60src and Akt-GSK3 activities upstream and downstream to PI 3-kinase, respectively.
Barel M; Balbo M; Le Romancer M; Frade R
Eur J Immunol; 2003 Sep; 33(9):2557-66. PubMed ID: 12938232
[TBL] [Abstract][Full Text] [Related]
19. Activation of Epstein-Barr virus/C3d receptor (gp140, CR2, CD21) on human B lymphoma cell surface triggers Cbl tyrosine phosphorylation, its association with p85 subunit, Crk-L and Syk and its dissociation with Vav.
Lottin-Divoux S; Jean D; Le Romancer M; Frade R
Cell Signal; 2006 Aug; 18(8):1219-25. PubMed ID: 16289966
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus binding to CD21, the virus receptor, activates resting B cells via an intracellular pathway that is linked to B cell infection.
Roberts ML; Luxembourg AT; Cooper NR
J Gen Virol; 1996 Dec; 77 ( Pt 12)():3077-85. PubMed ID: 9000100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
